- Home
- QTTB vs ACHL Comparison
QTTB vs ACHL Comparison
Compare QTTB & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- ACHL
- Stock Information
- Founded
- QTTB 2015
- ACHL 2016
- Country
- QTTB United States
- ACHL United Kingdom
- Employees
- QTTB N/A
- ACHL N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QTTB Health Care
- ACHL Health Care
- Exchange
- QTTB Nasdaq
- ACHL Nasdaq
- Market Cap
- QTTB 40.0M
- ACHL 46.0M
- IPO Year
- QTTB N/A
- ACHL 2021
- Fundamental
- Price
- QTTB $3.28
- ACHL $1.39
- Analyst Decision
- QTTB Buy
- ACHL Buy
- Analyst Count
- QTTB 8
- ACHL 2
- Target Price
- QTTB $29.14
- ACHL $4.00
- AVG Volume (30 Days)
- QTTB 215.6K
- ACHL 507.6K
- Earning Date
- QTTB 11-07-2024
- ACHL 11-14-2024
- Dividend Yield
- QTTB N/A
- ACHL N/A
- EPS Growth
- QTTB N/A
- ACHL N/A
- EPS
- QTTB N/A
- ACHL N/A
- Revenue
- QTTB N/A
- ACHL N/A
- Revenue This Year
- QTTB N/A
- ACHL N/A
- Revenue Next Year
- QTTB N/A
- ACHL N/A
- P/E Ratio
- QTTB N/A
- ACHL N/A
- Revenue Growth
- QTTB N/A
- ACHL N/A
- 52 Week Low
- QTTB $2.90
- ACHL $0.63
- 52 Week High
- QTTB $53.79
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- QTTB 27.36
- ACHL 80.39
- Support Level
- QTTB $2.90
- ACHL $1.10
- Resistance Level
- QTTB $3.47
- ACHL $1.41
- Average True Range (ATR)
- QTTB 0.25
- ACHL 0.04
- MACD
- QTTB 0.63
- ACHL 0.02
- Stochastic Oscillator
- QTTB 45.59
- ACHL 90.48
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.